CD8A and cancer: The assumption that immune phenotypes of cancers have a profound impact on their clinical course are in line with the results of an increasing number of publications showing a prognostic relevance of virtually all immune cell subtypes, i.e., CD3+ Tlymphocytes [2, 36], CD20+ B lymphocytes [51], CD8+ cytotoxic T cells, CD8+Ki67+ cytotoxic T cells, CD4+ helper T cells [52], FOXP3+ regulatory T cells [53], CD45RO memory T cells [2] and other subsets.